Sign up
Pharma Capital

Race Oncology director sees "extreme, untapped value" in company's cancer drug

Race Oncology (ASX:RAC) non-executive director Dr. John Cullity tells Proactive Investors the specialty pharmaceutical company is working on getting the company's cancer chemotherapy drug, Bisantrene, to market by 2021 or 2022.

Dr. Cullity says the drug treats leukemia, and specifically Acute Myeloid Leukaemia (AML), which affects around 3,000 patients in the U.S.

 

View full RAC profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.